Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial | Zendy

Sharon Salerno | Zendy; Jon D. Vogel | Zendy

Open Access

Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial

Author(s) -

Sharon Salerno,

Jon D. Vogel

Publication year - 2013

Publication title -

journal of pain research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.888

H-Index - 49

ISSN - 1178-7090

DOI - 10.2147/jpr.s46950

Subject(s) - medicine , opioid , bupivacaine , hydromorphone , anesthesia , ileostomy , adverse effect , analgesic , regimen , morphine , multimodal therapy , fast track , surgery , receptor

Postoperative opioid use following ileostomy reversal procedures contributes to postoperative ileus. We assessed the impact of a liposome bupivacaine-based, opioid-sparing multimodal analgesia regimen versus a standard opioid-based analgesia regimen on postsurgical opioid use. We also assessed health economic outcomes in patients undergoing ileostomy reversal at our institution, which employs an enhanced recovery discharge protocol.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research